Asciminib interactions
Full monograph for AsciminibCheck it against another medicine
Medicines
477 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adalimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of… | 6 sources — open the full entry |
| Avatrombopag | Majorsource also lists Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 2C9 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Baricitinib | Major | Synergy | Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. | 3 sources — open the full entry |
| Clozapine | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 4 sources — open the full entry |
| Colchicine | Major | Absorption · Excretion | Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the serum concentrations of colchicine. The mechanism involves enhanced… | 29 sources — open the full entry |
| Deferiprone | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 4 sources — open the full entry |
| Deucravacitinib | Major | Synergy | Coadministration of deucravacitinib with other immunosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. | 1 sources — open the full entry |
| Etanercept | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of… | 6 sources — open the full entry |
| Fosphenytoin Sodium | Major | Metabolism | Coadministration of asciminib with CYP450 2C9 substrates that are also potent CYP450 3A4 inducers such as phenytoin or fosphenytoin may lead to altered plasma… | 1 sources — open the full entry |
| Golimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of… | 6 sources — open the full entry |
| Imatinib Mesylate | Major | Metabolism | Coadministration with imatinib may increase the plasma concentrations of asciminib. The proposed mechanism is inhibition of asciminib metabolism via CYP450… | 2 sources — open the full entry |
| Infliximab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of… | 6 sources — open the full entry |
| Itraconazole | Major | Others | Coadministration with itraconazole oral solution containing hydroxypropyl-beta-cyclodextrin may decrease the plasma concentrations of asciminib and reduce its… | 2 sources — open the full entry |
| Leflunomide | Major | Synergy | The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to… | 2 sources — open the full entry |
| Phenytoin Sodium | Major | Metabolism | Coadministration of asciminib with CYP450 2C9 substrates that are also potent CYP450 3A4 inducers such as phenytoin or fosphenytoin may lead to altered plasma… | 1 sources — open the full entry |
| Relugolix | Major | Absorption | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the… | 1 sources — open the full entry |
| Relugolix + Estradiol + Norethindrone | Major | Absorption · Metabolism | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the…3 documented mechanisms | 2 sources — open the full entry |
| Rotavirus Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of… | 10 sources — open the full entry |
| Tofacitinib | Major | Synergy | Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. | 1 sources — open the full entry |
| Upadacitinib | Major | Synergy | Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. | 1 sources — open the full entry |
| Venetoclax | Major | Absorption | Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter. | 3 sources — open the full entry |
| Warfarin Sodium | Majorsource also lists Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 2C9 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Yellow Fever Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of… | 10 sources — open the full entry |
| Abiraterone Acetate | Moderate | Others | It is uncertain whether asciminib causes clinically significant prolongation of the QT interval of the electrocardiogram. | 2 sources — open the full entry |
| Acalabrutinib | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Acyclovir + Hydrocortisone | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Afatinib Dimaleate | Moderate | Distribution | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 1 sources — open the full entry |
| Albendazole | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Alfuzosin Hydrochloride | Moderate | Others | It is uncertain whether asciminib causes clinically significant prolongation of the QT interval of the electrocardiogram. | 2 sources — open the full entry |
| Alprazolam | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide | Moderate | Synergy | Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in… | 6 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide + Simethicone | Moderate | Synergy | Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in… | 6 sources — open the full entry |
| Ambrisentan | Moderate | Others | Coadministration with asciminib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. In vitro… | 1 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Others | It is uncertain whether asciminib causes clinically significant prolongation of the QT interval of the electrocardiogram. | 2 sources — open the full entry |
| Amisulpride | Moderate | Others | It is uncertain whether asciminib causes clinically significant prolongation of the QT interval of the electrocardiogram. | 2 sources — open the full entry |
| Amitriptyline Hydrochloride | Moderate | Others | It is uncertain whether asciminib causes clinically significant prolongation of the QT interval of the electrocardiogram. | 2 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxide | Moderate | Others | It is uncertain whether asciminib causes clinically significant prolongation of the QT interval of the electrocardiogram. | 2 sources — open the full entry |
| Amlodipine Besilate | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Amlodipine Besilate + Atenolol | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is…2 documented mechanisms | 1 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Amlodipine Besilate + Olmesartan Medoxomil | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Amlodipine Besilate + Telmisartan | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Amlodipine Besilate + Valsartan | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Apalutamide | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of asciminib. Asciminib is primarily metabolized by CYP450… | 1 sources — open the full entry |
| Apixaban | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of apixaban, which is a substrate of both… | 3 sources — open the full entry |
| Aprepitant | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Aripiprazole | Moderate | Others | It is uncertain whether asciminib causes clinically significant prolongation of the QT interval of the electrocardiogram. | 2 sources — open the full entry |
| Arsenic Trioxide | Moderate | Others | It is uncertain whether asciminib causes clinically significant prolongation of the QT interval of the electrocardiogram. | 2 sources — open the full entry |
| Artemether + Lumefantrine | Moderate | Metabolism · Others | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is…2 documented mechanisms | 3 sources — open the full entry |
Food & lifestyle
high-fat foods
ModerateAbsorption
Food may reduce the oral bioavailability of asciminib. When a single 40 mg dose of asciminib was administered with a low-fat meal (400 calories; 25% fat) in healthy volunteers, asciminib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 35% and 30%, respectively, compared to asciminib administered in the fasted state.
What to do: To ensure adequate asciminib exposures, food consumption should be avoided for at least 2 hours before and 1 hour after taking asciminib.
2 sources
- "Product Information. Scemblix (asciminib)." Novartis Pharmaceuticals (2021):
- "Product Information. Scemblix (asciminib)." Novartis Pharmaceuticals UK Ltd (2022):
Conditions
Conditions in which Asciminib needs care, as documented in this source.
Cardiotoxicity
MajorCardiovascular toxicity has been reported with asciminib in patients with preexisting cardiovascular conditions or risk factors for cardiovascular disease. Reports of cardiovascular toxicity have included ischemia, arterial thrombotic and embolic conditions, and cardiac failure. Arrhythmia, including QTc prolongation, has been reported. Monitor patients with history of cardiovascular risk factors for cardiovascular signs and symptoms. Treat as clinically indicated. For cardiovascular toxicity, temporarily withhold, reduce dose, or permanently discontinue therapy, based on persistence of cardiovascular toxicity.
1 source
- "Product Information. Scemblix (asciminib)." Novartis Pharmaceuticals (2021):
Pancreatitis
MajorAsciminib can cause increases in serum lipase. Patients with a previous history of pancreatitis might be at increased risk and should be monitored carefully for lipase elevations and any abdominal symptoms. Serum lipase should be monitored monthly and as clinically indicated. If lipase and amylase elevations are accompanied by abdominal symptoms, hold therapy, and rule out pancreatitis.
1 source
- "Product Information. Scemblix (asciminib)." Novartis Pharmaceuticals (2021):
Hypertension
ModerateThe use of asciminib may cause hypertension. Blood pressure should be well-controlled prior to initiating asciminib and treated as needed with standard anti-hypertensive therapy. For persistent hypertension despite anti-hypertensive medications, temporarily withhold, reduce dose, or permanently discontinue therapy, based on the persistence of hypertension.
1 source
- "Product Information. Scemblix (asciminib)." Novartis Pharmaceuticals (2021):